Q32 Bio (QTTB) EBIT (2017 - 2026)

Q32 Bio's EBIT history runs 10 years deep, the most recent figure standing at -$7.7 million for Q1 2026.

• On a quarterly basis, EBIT rose 36.85% year-over-year to -$7.7 million in Q1 2026; TTM through Mar 2026 was $21.4 million, a 133.72% increase from a year earlier, with the FY2025 full-year figure at $16.9 million, up 125.57% from the prior year.
• EBIT slipped to -$7.7 million in Q1 2026 per QTTB's latest filing, from $45.9 million in the prior quarter.
• Across five years, EBIT topped out at $45.9 million in Q4 2025 and bottomed at -$37.6 million in Q1 2022.
• The 5-year median for EBIT is -$14.5 million (2024), against an average of -$14.0 million.
• Across the five-year window, EBIT tumbled 3285.96% in 2022 and soared 415.84% in 2025, its largest moves.
• Year by year, EBIT stood at -$34.5 million in 2022, then grew by 25.18% to -$25.8 million in 2023, then surged by 43.72% to -$14.5 million in 2024, then surged by 415.84% to $45.9 million in 2025, then tumbled by 116.83% to -$7.7 million in 2026.
• Per Business Quant, the three latest QTTB EBIT figures stand at -$7.7 million (Q1 2026), $45.9 million (Q4 2025), and -$7.6 million (Q3 2025).